NHI Stock Analysis: National Health Investors | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 3.604m USD | 12M Return: -3.6% | US63633D1046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.6M
EPS Trend: 79.5%
Qual. Beats: -2
Rev. Trend: 93.6%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
National Health Investors, Inc. (NHI) is a self-managed real estate investment trust that provides capital to the senior housing and healthcare facility sector through sale-leaseback transactions, joint ventures, mortgage financing, and mezzanine financing. The company invests in need-driven and discretionary properties spanning the continuum of senior care, including independent living, assisted living, memory care, entrance-fee retirement communities, senior living campuses, skilled nursing facilities, and specialty hospitals.
NHI was founded and incorporated in 1991 in Maryland and is headquartered in Murfreesboro, Tennessee. It trades on the NYSE under the ticker NHI and is classified within the Health Care REITs sub-industry of the Real Estate sector.
Healthcare REITs like NHI typically generate revenue through long-term triple-net leases with operator tenants, which shift property-level operating expenses (taxes, insurance, maintenance) to the lessee. This structure allows the REIT to focus on capital deployment and asset management rather than facility operations, distinguishing it from operators that run the properties themselves.
- Senior housing occupancy recovery lifts SHOP segment revenue
- Interest rate hikes pressure REIT borrowing costs and cap rates
- Skilled nursing Medicare reimbursement shifts impact portfolio cash flows
| Net Income: 166.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.57 > 1.0 |
| NWC/Revenue: -50.58% < 20% (prev -24.24%; Δ -26.33% < -1%) |
| CFO/TA 0.08 > 3% & CFO 250.9m > Net Income 166.8m |
| Net Debt (1.25b) to EBITDA (316.0m): 3.97 < 3 |
| Current Ratio: 0.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.5m) vs 12m ago 3.58% < -2% |
| Gross Margin: 44.74% > 18% (prev 96.72%; Δ -51.98% > 0.5%) |
| Asset Turnover: 15.32% > 50% (prev 12.93%; Δ 2.39% > 0%) |
| Interest Coverage Ratio: 3.90 > 6 (EBIT TTM 223.4m / Interest Expense TTM 57.3m) |
| A: -0.07 (Total Current Assets 314.7m - Total Current Liabilities 533.9m) / Total Assets 2.96b |
| B: -0.13 (Retained Earnings -396.9m / Total Assets 2.96b) |
| C: 0.08 (EBIT TTM 223.4m / Avg Total Assets 2.83b) |
| D: 1.14 (Book Value of Equity 1.57b / Total Liabilities 1.38b) |
| Altman-Z'' = 0.80 = B |
| DSRI: 0.48 (Receivables 209.3m/354.0m, Revenue 433.6m/348.7m) |
| GMI: 2.16 (GM 96.72% / 44.74%) |
| AQI: 12.17 (AQ_t 0.03 / AQ_t-1 0.00) |
| SGI: 1.24 (Revenue 433.6m / 348.7m) |
| TATA: -0.03 (NI 166.8m - CFO 250.9m) / TA 2.96b) |
| Beneish M = 4.39 (Cap -4..+1) = D |
As of September 02, 2026, the stock is trading at USD 72.27 with a total of 336,120 shares traded. Over the past week, the price has changed by -2.68%, over one month by -7.23%, over three months by +0.28% and over the past year by -3.61%.
Current recommended Stop Loss: 68.50 (which is 5.2% or 2.4 ATR below the current price).
National Health Investors has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy NHI.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 82.1 | 13.6% |
P/E Trailing = 21.211
P/E Forward = 18.1488
P/S = 8.2707
P/B = 2.2923
P/EG = 4.7612
Revenue TTM = 433.6m USD
EBIT TTM = 223.4m USD
EBITDA TTM = 316.0m USD
Long Term Debt = 959.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 438.0m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (calculated: Debt 1.28b - CCE 30.4m)
Enterprise Value = 4.86b USD (3.60b + Debt 1.28b - CCE 30.4m)
Interest Coverage Ratio = 3.90 (Ebit TTM 223.4m / Interest Expense TTM 57.3m)
EV/FCF = 20.61x (Enterprise Value 4.86b / FCF TTM 235.7m)
FCF Yield = 4.85% (FCF TTM 235.7m / Enterprise Value 4.86b)
FCF Margin = 54.37% (FCF TTM 235.7m / Revenue TTM 433.6m)
Net Margin = 38.47% (Net Income TTM 166.8m / Revenue TTM 433.6m)
Gross Margin = 44.74% ((Revenue TTM 433.6m - Cost of Revenue TTM 239.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev 31.12%)
Tobins Q-Ratio = 1.64 (Enterprise Value 4.86b / Total Assets 2.96b)
Interest Expense / Debt = 4.46% (Interest Expense 57.3m / Debt 1.28b)
Taxrate = 1.31% (732k / 56.1m)
NOPAT = 220.5m (EBIT 223.4m * (1 - 1.31%))
Current Ratio = 0.59 (Total Current Assets 314.7m / Total Current Liabilities 533.9m)
Debt / Equity = 0.82 (Debt 1.28b / totalStockholderEquity, last quarter 1.57b)
Debt / EBITDA = 3.97 (Net Debt 1.25b / EBITDA 316.0m)
Debt / FCF = 5.32 (Net Debt 1.25b / FCF TTM 235.7m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.89% (Net Income 166.8m / Total Assets 2.96b)
RoE = 10.96% (Net Income TTM 166.8m / Total Stockholder Equity 1.52b)
RoCE = 9.00% (EBIT 223.4m / Capital Employed (Equity 1.52b + L.T.Debt 959.8m))
RoIC = 7.75% (NOPAT 220.5m / Invested Capital 2.85b)
WACC = 4.80% (E(3.60b)/V(4.89b) * Re(4.94%) + D(1.28b)/V(4.89b) * Rd(4.46%) * (1-Tc(0.01)))
Discount Rate = 4.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.55 | Cagr: 5.03%
[DCF] Terminal Value 77.97% ; FCFF base≈221.0m ; Y1≈253.3m ; Y5≈372.8m
[DCF] Fair Price = 88.71 (EV 5.61b - Net Debt 1.25b = Equity 4.36b / Shares 49.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 79.48 | EPS CAGR: 10.55% | SUE: -1.07 | # QB: -2
Revenue Correlation: 93.65 | Revenue CAGR: 11.09% | SUE: 1.58 | # QB: 4
EPS current Quarter (2026-09-30): EPS=4.56 | Chg30d=+388.61% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=14.55 | Chg30d=+296.98% | Revisions=+25% | GrowthEPS=+396.6% | GrowthRev=+19.1%
EPS next Year (2027-12-31): EPS=3.25 | Chg30d=-5.90% | Revisions=-25% | GrowthEPS=-77.7% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: +17% (up=2, down=1)